Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE013 (USA) (Dr. Clarke)
· consented 2022-12-22
Adverse events
5
Serious AEs
1
Open data queries
0
Luna dropout signal
–
Adverse events
mild
assessed
2026-08-18
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-01-21 (study day 14); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-01-26 (study day 19); relationship: not assessed
severe
serious
assessed
2026-08-18
Grade 3 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-01-30 (study day 23); relationship: not assessed; serious criteria: hospitalization
mild
assessed
2026-08-18
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-03-03 (study day 55); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-03-12 (study day 64); relationship: Y
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.